Editorials

Value of the Multibiomarker Disease Activity Score to Predict Remission in RA: What Does the Evidence Show?  R. Fleischmann .......................... 443

Methotrexate in Our Hearts
L. Ljung, M. Holmqvist .......................... 447

How Important Are the Standard Measures in Assessing the Clinical Outcomes in Psoriatic Arthritis in Real-world Settings?
F. Iannone ........................................ 450

Methotrexate in Giant Cell Arteritis Deserves a Second Chance — A High-dose Methotrexate Trial Is Needed
E. Brouwer, K.S. van der Geest, M. Sandovici ................. 453

Rheumatoid Arthritis

Fertility and Ovarian Reserve among Women with RA
A.M. Eudy, G. McDaniel, W.W. Hurd, M.E. Clowse .............. 455

Cost-effective Tapering Algorithm in Patients with RA: Combination of Multibiomarker Disease Activity Score and Autoantibody Status
M. Hagen, M. Englbrecht, J. Haschka, et al .................. 460

Associations Between Methotrexate Use and the Risk of Cardiovascular Events in Patients with Elderly-onset RA
J. Widdifield, M. Abrahamowicz, J.M. Paterson, et al ........ 467

Psoriatic Arthritis

Predictors of Achieving Remission among Patients with PsA Initiating a Tumor Necrosis Factor Inhibitor
A. Ogdie, J.L. Palmer, J. Greenberg, et al ....................... 475

Systemic Lupus Erythematosus

Disease Damage Influences Cardiovascular Risk Reclassification Based on Carotid Ultrasound in Patients with SLE
J.C. Quevedo-Abeledo, I. Rúa-Figueroa,
H. Sánchez-Pérez, et al ................................ 483

Gout

Hepatic Safety of Febuxostat Compared with Allopurinol in Gout Patients with Fatty Liver Disease
J.S. Lee, J. Won, O.C. Kwan, et al ......................... 527

Other

Position Statement: A Pragmatic Approach for Medical Cannabis and Patients with Rheumatic Diseases
M.A. Fitzcharles, O. Zahedi Niaki, W. Hauser,
G. Hazlewood, and the Canadian Rheumatology Association ................................ 532

Contents continued on page xii